When was Celixir founded?

Celixir was founded in 2009 and raised its 1st funding round 5 years after it was founded.

Where is Celixir located?

Celixir is headquartered in Cardiff, United Kingdom. It is registered at CELIXIR HOUSE STRATFORD-UPON-AVON BUSINESS & TECHNOLOGY PARK,INNOVATION WAY,STRATFORD-UPON-AVON,ENGLAND,CV37 7GZ.

Which legal entities is Celixir associated with?

Celixir is associated with CELIXIR LIMITED and 1 other.

How many employees does Celixir have?

As of Mar 31, 2021, the latest employee count at Celixir is 1.

Is Celixir a funded company?

Celixir is a funded company, having raised a total of $2.58M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 01, 2014.

When was the latest funding round of Celixir?

Celixir's latest funding was a $***** Seed round on Mar 06, 2018, with participation from 0 investor.

Where does Celixir rank among its competitors?

Celixir ranks 123rd amongst 365 active competitors, of which 111 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Vor Biopharma, which secured $150M in Dec, 2025.

Who are the top competitors of Celixir?

Celixir's top competitors include argenx, Tenaya Therapeutics and Vor Biopharma. Among them, Vor Biopharma secured the most recent funding round in December, 2025.

Celixir - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Celixir is a UK-based, late-clinical stage biopharma developing regenerative therapies for serious indications, notably, cardiac diseases. The company was previously called Cell Therapy Limited and changed its name in 2016. The company's platform technology allows them to provide an ‘off-the-shelf’ approach to deliver their regenerative medicines. Their lead candidate is "Heartcel" which is an Immunomodulatory Progenitor Cell therapy. It is designed to treat patients with ischemic heart disease undergoing coronary artery bypass graft. They are injected around cardiac scar tissue via a single application during bypass surgery. The candidate is in Phase 2 trials. The second candidate is Tendoncel entering Phase 3 trials, which is a platelet lysate based therapy. It is indicated for regenerating injured tendons near the surface of the skin. The 3rd candidate is Myocardion, which is to enter clinical trials. They are Mesodermal Progenitor cells and are indicated for mild to moderate heart failure.

Website: celixir.com
Social
Email ID: *****@celixir.com
Registered Address: CELIXIR HOUSE STRATFORD-UPON-AVON BUSINESS & TECHNOLOGY PARK,INNOVATION WAY,STRATFORD-UPON-AVON,ENGLAND,CV37 7GZ

Key Metrics

Founded Year

2009

Location

Cardiff, United Kingdom

Stage

Seed

Total Funding

$2.58M in 2 rounds

Latest Funding Round

Seed, Mar 06, 2018, $*****

Investors

Regah Ventures & 3 more

Ranked

123^rd among 365 active competitors

Employee Count

1 as on Mar 31, 2021

Similar Companies

Tenaya Therapeutics & 352 more

View Celixir's full profile

Celixir is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CELIXIR LIMITED CIN: 10541091 , United Kingdom, Active	Dec 27, 2016	-	4 (As on Mar 31, 2024)
Celixir plc CIN: 10541091 , Germany, Active	Dec 27, 2016	-	-

Celixir has raised a total funding of $2.58M over 2 rounds. Its first funding round was on Dec 01, 2014. Celixir has 4 institutional investors.

Here is the list of recent funding rounds of Celixir:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 06, 2018	8646426	Seed	7324200	8872559	7547748	5581740
Dec 01, 2014	9960834	Seed	2308856	6775022	1682432	4481455

Access funding benchmarks and valuations. Sign up today!

View details of Celixir's funding rounds and investors

The founders of Celixir are Martin Evans and Ajan Reginald.

Here are the details of Celixir's key team members:

Martin Evans: Co-Founder & President of Celixir and founder of 1 other company. They serve on the board of 1 company.
Ajan Reginald: CEO of Celixir.

View details of Celixir's Founder profiles and Board Members

Celixir's employee count trend

Celixir has 1 employees as of Mar 21. Here is Celixir's employee count trend over the years:

Uncover Celixir's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Celixir include argenx, Tenaya Therapeutics and Vor Biopharma. Here is the list of Top 10 competitors of Celixir, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Forbion & 20 others	72/100
2nd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, RA Capital Management & 7 others	70/100
3rd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
4th	Esperion Therapeutics 1998, Ann Arbor (United States), Public	Developer of lipoprotein cholesterol (LDL-C) lowering therapies	$107M	Alta Partners, Aisling Capital & 15 others	67/100
5th	Kiniksa Pharmaceuticals 2015, Lexington (United States), Public	Developer of therapeutics for multiple diseases treatment	$320M	Sofinnova Investments, Fidelity Investments ... & 8 others	67/100
6th	Ossium Health 2016, San Francisco (United States), Series C	Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning	$125M	Vivo Capital, CPMG & 12 others	65/100
7th	Edgewise Therapeutics 2017, Boulder (United States), Public	Developer of therapeutics for skeletal and cardiac muscle diseases	$145M	Viking Global Investors, USVP & 11 others	65/100
8th	Cellino 2017, Cambridge (United States), Series A	Developer of autologous cell therapies	$125M	Khosla Ventures, 8VC & 7 others	65/100
9th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Quaker Partners Management, Athyrium Capital Management ... & 4 others	64/100
10th	MyoKardia 2012, San Francisco (United States), Acquired	Developing drugs for treating genetic heart diseases	$98M	Perceptive Advisors, Sanofi & 6 others	63/100
123rd	Celixir 2009, Cardiff (United Kingdom), Seed	Stem Cell and Regenerative therapy for heart disease	$2.58M	Regah Ventures, Blueray Capital & 2 others	39/100